Abstract
Eisai currently ranks 18th of all researched-based companies in terms of
pharmaceutical sales. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
From April to September 2005, Eisai's net sales were ¥282,629 million, an 8%
increase over the previous fiscal year's interim period, due to a rise in
sales of Aricept (+18% to ¥89,991 million) and Pariet (+10% to ¥71,576
million). Pharmaceutical sales improved by 9% to ¥272,371 million. Operating
income was up by 9% to ¥45,269 million, and net income also advanced by 9% to
¥30,158 million. Expenditure on R&D increased by 19% to ¥44,400 million.
Geographical sales were as follows: Japan (+4% to ¥139,576 million), North
America (+11% to ¥113,958 million), Europe (+10% to ¥21,198 million) and Asia
and others (+37% to ¥7,897 million) reflecting the fact that Eisai is less
reliant on the Japanese domestic market than its competitors.
R&D Pipeline Overview
- E2007 is an oral AMPA type glutamate receptor antagonist,
undergoing multiple Phase II trials targeted at Parkinson's disease and
multiple sclerosis in Europe and epilepsy (US/Europe). Filing for epilepsy in
the US is expected 2007.
- E7389 is a synthetic analogue of halichondrin B (HB), a natural
product shown, in preclinical studies, to have highly potent anticancer
activity in vitro and in vivo. Phase II studies started in the US in 2004, and
filings are expected in 2007.
Major Products Forecast to 2010
- Aricept (CNS)
- Methycobol (CNS)
- Pariet (Gastrointestinal)
- Selbex (Gastrointestinal)
- Glakay (Osteoporosis)
- Iomeron (Contrast agent)
- Myonal (CNS)
- Azeptin (Anti-allergenic)
- Nitrol-R (Cardiovascular)
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Expenditure
- Capital Expenditure
- Capital Expenditure by Business Area
- Capital Expenditure by Business Area
- R&D Expenditure
- R&D Expenditure and Capital Expenditure
- Divisional Performance
- Sales By Business Area
- Sales by Business Area
- Operating Income (Loss) by Business Area
- Operating Income (Loss) by Business Area
- Total Assets by Business Area
- Total Assets by Business Area, 2005
- Geographic Performance
- Sales by Destination
- Sales by Destination, 2005
- Sales by Origin
- Sales by Origin
- Operating Income (Loss) by Geographical Area
- Total Assets by Geographical Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Employees by Geographic Segment, 2005
- Employees and Productivity
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecasts
- Sales of Current Major Products (2001A-2010E)
- Conclusions
PRODUCT PORTFOLIO/RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales of Major Products, 2005
- R&D Pipeline
- Neurology - Products
- Major Launched Products
- Aricept
- Sales
- Key Markets/Indications/Formulations
- Further development
- Patents/Generic Competition
- Competitor Products
- Sales Forecast
- Aricept Sales (2000A-2010E)
- Methycobal/Nabolin S
- Sales
- Key Markets/Indications/Formulations
- Competitor products
- Sales Forecast
- Methycobal Sales (2000A-2010E)
- Myonal
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Myonal Sales (2000A-2010E)
- Zonegran
- Other Neurology Products
- Neurology - R&D
- Agilect
- E2007
- E2014
- E2070
- Inovelon
- Neurology - Summary
- Growth Potential
- Limiting Factors
- Gastroenterology - Products
- Major Launched Products
- Aciphex/Pariet
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits/Generic Competition
- Competitor Products
- Sales Forecast
- Aciphex/Pariet sales (2000A-2010E)
- Selbex
- Sales
- Key Markets/Indications
- Competitor Products
- Patents/Lawsuits
- Sales Forecast
- Selbex Sales (2000A-2010E)
- Gastroenterology - R&D
- Gastroenterology - Summary
- Growth Potential
- Limiting Factors
- Cardiovascular and Respiratory - Products
- Major Launched Products
- Azeptin
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Azeptin Sales (2000A-2010E)
- Nitrol-R
- Sales
- Competitor Products
- Sales Forecast
- Nitrol-R Sales (2000A-2010E)
- Cleactor
- Cardiovascular and Respiratory - R&D
- Cardiovascular and Respiratory - Summary
- Growth Potential
- Limiting Factors
- Metabolic - Products
- Major Launched Products
- Glakay/KayTwo
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Glakay/KayTwo sales (2000A-2010E)
- Glucagon G Novo
- Sales
- Key Markets/Indications
- Sales Forecast
- Glucagon G Novo sales (2000A-2010E)
- Metabolic - R&D
- Metabolic - Summary
- Growth Potential
- Limiting Factors
- Diagnostics - Products
- Major Launched Products
- Iomeron
- Sales
- Key Markets/Indications
- Sales forecast
- Iomeron Sales (2000A-2010E)
- Diagnostics - R&D
- Diagnostics - Summary
- Anti-infectives - Products
- Major Launched Products
- Rulid
- Sales
- Key Markets/Indications
- Anti-infectives - R&D
- Eritoran
- Ravuconazole (ER-30346)
- Anti-infectives - Summary
- Growth Potential
- Limiting Factors
- Oncology - R&D
- E0167
- E7080
- E7389
- E7820
- Indislam
- E7010
- E7107
- E7934
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Other - Products
- Other - R&D
- Adalimumab (D2E7)
- E6040
- Iguratimod
APPENDIX 1- FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- Abbott
- 21st June 1999
- 5th July 2000
- 27th April 2004
- 11th April 2005
- Dainippon Sumitomo Pharma
- Elan Corporation plc
- 29th September 2000
- 27th April 2004
- 9th February 2006
- GlaxoSmithKline plc
- 1st April 2004
- 26th May 2005
- Janssen Pharmaceutica
- 15th April 1997
- 7th January 2004
- Novartis
- Pfizer
- 28th November 1994
- 25th July 2002
- 2nd January 2003
- 28th September 2005
- sanofi-aventis/Ajinomoto
- 20th March 2002
- 12th September 2005
- Teva Pharmaceutical Industries Ltd
- TorreyPines Therapeutics Inc
- Toyama Chemical Co Ltd
- Wyeth
- Others
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Major Domestic Subsidiaries
- Major North American Subsidiaries
- Major European Subsidiaries
- Major Asian Subsidiaries
- Joint-Venture Companies
APPENDIX 6 - PRODUCT INDEX
|
